Bringing Groundbreaking Treatments to Patients with Psychiatric and Neurodegenerative Diseases

Unleashing unique properties and biological effects of Noble gases for treatment of PTSD, Autism, Dementia

Combining revolutionary portable inhalation device with a safe therapeutic

Accelerated pathway of clinical development

Vlad Bogin, MD, FACP (Chairman of the Board)
Dr. Bogin started his medical training at Moscow Medical Academy, then trained at Yale and Brown Universities and received his postgraduate training at the University of Rochester where he was also elected to a chief medical resident position. Dr. Bogin has been involved in the drug development cycle for over 15 years, from basic discovery research to clinical trial design and multinational phase III and IV trials. As a director at Boehringer Ingelheim he was in charge of late stage development of a leading cardiology product. As the Chairman of the Board at Medistem Inc., Dr. Bogin was instrumental in advancing the company from the preclinical to clinical stage, from a non-reporting to a fully reporting publicly trading company, and for a subsequent successful liquidity event in early 2014. Dr. Bogin maintains active medical license and hospital privileges and is an advisor to numerous companies and non-profit organizations. Dr. Bogin is an author of numerous peer-reviewed articles, book chapters and patents.

Dr. Thomas Ichim, PhD.
Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Subsequent to the acquisition of Medistem by Intrexon, in a deal worth $26 million, Dr. Ichim was brought on to the parent company in its cell engineering unit as Vice President of Cellular Therapy. Dr. Ichim has authored over a 100 peer-reviewed papers, is inventor of over 50 patents and patent applications, and is peer-reviewer and editor of several international academic journals.

Dr. Yan Stillman, DMD.
Dr. Stillman is the Managing Partner of Wilshire Dental Group and a serial entrepreneur with significant interest in the biopharmaceutical sphere. As a business advisor to Medistem Inc. Dr. Stillman played an active role in this company’s business development and fundraising activities. He is also a founding partner of Amerident, a Chief Executive Officer of the California Chapter of the Russian American Dental Association and an Administrative Director of Avantgarde Pediatric Dental Group.

Vladimir Zaharchook, PhD
Dr. Zaharchook is a successful real estate developer and realtor in Portland, OR. He is a serial investor in biopharmaceutical companies. He served as a Vice-Chairman of the Board at Medistem, Inc. and helped guide this company through its transition to public markets and acquisition process. He received his Masters and PhD degrees at the St. Petersburgh University of Economics and Finance.